Trabbic, Kevin R.
Kleski, Kristopher A.
Shi, Mengchao
Bourgault, Jean-Paul
Prendergast, Jillian M.
Dransfield, Daniel T.
Andreana, Peter R. http://orcid.org/0000-0002-5300-6700
Funding for this research was provided by:
National Cancer Institute (R01 CA156661)
National Cancer Institute (R43 CA186326)
U.S. Department of Health and Human Services (N261200700063C, N261200900034C)
Article History
Received: 27 February 2017
Accepted: 9 July 2018
First Online: 20 July 2018
Compliance with ethical standards
:
: Kevin R. Trabbic, Kristopher A. Kleski, Mengchao Shi, Jean-Paul Bourgault, and Peter R. Andreana declare that they have no conflict of interest. The glycan array described is owned by and/or licensed to Siamab Therapeutics, Inc. in which Jillian M. Prendergast and Daniel T. Dransfield have a business and/or financial interest.
: C57BL/6 male mice (6 weeks) were obtained from Jackson Laboratories and maintained by the DLAR at the University of Toledo. All animal protocols were approved and performed in compliance with the relevant laws and institutional guidelines set forth by the IACUC of the University of Toledo (Protocol 107956). SHO<sup>®</sup> 4-week-old female mice (Crl:SHO<sup>®</sup>-Prkdc<sup>scid</sup>Hr<sup>hr</sup>) were obtained from Charles River Laboratories and maintained by the DLAR at the University of Toledo. All animal protocols were approved and performed in compliance with the relevant laws and institutional guidelines set forth by the IACUC of the University of Toledo (Protocol Number 108420). The Sp2/0-Ag14 (ATCC CRL 1581) cell line was purchased from the American-Type Culture Collection. The MCF-7 (ATCC HTB-22) cell line and the HCT-116 (ATCC CCL-247) cell line was from Henry Ford Health Systems.